FAQS

Frequently asked questions

SARCLISA is a prescription medicine used in combination with pomalidomide and dexamethasone to treat adults who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor, to treat multiple myeloma.

It is not known if SARCLISA is safe and effective in children.

See more about how SARCLISA works.

SARCLISA is the first and only treatment to be approved based on a large Phase 3 study when given together with Pomalyst® (pomalidomide) and dexamethasone (Pd), 2 other standard medicines that are used to treat multiple myeloma.

Learn more about how SARCLISA was studied.

SARCLISA was approved by the FDA based on the results of a large Phase 3 study.

See the results of the SARCLISA study.

SARCLISA may cause serious side effects, including:

  • Infusion reactions. Infusion reactions are common with SARCLISA and can sometimes be severe.
  • Your healthcare provider will prescribe medicines before each infusion of SARCLISA to help decrease your risk for infusion reactions or to help make any infusion reaction less severe. You will be monitored for infusion reactions during each dose of SARCLISA.

    Your healthcare provider may slow down or stop your infusion, or completely stop treatment with SARCLISA, if you have an infusion reaction.

    Tell your healthcare provider right away if you develop any of the following symptoms of infusion reaction during or within 24 hours after an infusion of SARCLISA:

    — feeling short of breath

    — cough

    — chills

    — nausea

  • Decreased white blood cell counts. Decreased white blood cell counts are common with SARCLISA and certain white blood cells can be severely decreased. You may have an increased risk of getting certain infections, such as upper and lower respiratory infections.
  • Your healthcare provider will check your blood cell counts during treatment with SARCLISA. Your healthcare provider may prescribe an antibiotic or antiviral medicine to help prevent infection, or a medicine to help increase your white blood cell counts during treatment with SARCLISA.

    Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA.

  • Risk of new cancers. New cancers have happened in people during treatment with SARCLISA. Your healthcare provider will monitor you for new cancers during treatment with SARCLISA.
  • Change in blood tests. SARCLISA can affect the results of blood tests to match your blood type. Your healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA. Tell all of your healthcare providers that you are being treated with SARCLISA before receiving blood transfusions.

The most common side effects of SARCLISA include:

  • lung infection (pneumonia)
  • decreased red blood cell counts (anemia)
  • upper respiratory tract infection
  • decreased platelet counts (thrombocytopenia)
  • diarrhea

These are not all the possible side effects of SARCLISA. For more information, ask your healthcare provider or pharmacist.

Please see full Prescribing Information, including Patient Information.

SARCLISA is given by a doctor or nurse into your vein as an intravenous (IV) infusion. SARCLISA is given in 4-week treatment periods, called cycles. For the first cycle, SARCLISA is given once a week. For all following treatment cycles, SARCLISA is given once every 2 weeks.

Learn more about receiving SARCLISA.

The CareASSIST Patient Support Program offers resource support for patients who have been prescribed SARCLISA. Once you are enrolled in CareASSIST for SARCLISA, a Patient Access Specialist can help identify support services that may be available to you.

Call 1-833-WE+CARE (1-833-930-2273), Mon – Fri, 9 AM – 8 PM ET, or visit SanofiCareAssist.com/sarclisa.

Learn more about support for patients.

CareASSIST from Sanofi Genzyme helps eligible patients with access and reimbursement, financial assistance, and resource support, including the CareASSIST Copay Program.

Call 1-833-WE+CARE (1-833-930-2273), Mon – Fri, 9 AM – 8 PM ET, or visit SanofiCareAssist.com/sarclisa.

Learn more about paying for SARCLISA.

Relapse is when multiple myeloma returns after a previously effective treatment.

Refractory is when multiple myeloma is not responding to treatment.

Learn more about relapsed refractory multiple myeloma.